BIOMAT Database Logo BIOMAT Database Logo

Identification of human T cell hybridoma-derived macrophage activating factor as interleukin-2. 1993

N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Division of Chemical Toxicology and Immunochemistry, Faculty of Pharmaceutical Sciences, University of Tokyo.

Macrophages are activated by a two-step mechanism involving at least two kinds of factors, a priming and a triggering factor, to become cytotoxic to various tumor cells. In the present study, we purified macrophage-activating factor for cytotoxicity I (MAF-C I), defined as a priming macrophage activating factor (MAF), by about 1,600-fold from the culture supernatant of a human T cell hybridoma, H3-E9-6, by a series of chromatographic procedures. We identified MAF-C I activity released from H3-E9-6 cells as interleukin-2 (IL-2) from the following findings. (i) The physicochemical properties of MAF-C I and IL-2 were almost identical. (ii) Purified MAF-C I active fraction also showed T cell proliferating activity. (iii) MAF-C I activity in the purified fraction was completely neutralized by anti-IL-2 antibodies. (iv) Human recombinant IL-2 (rIL-2), at a suboptimal dose, and lipopolysaccharide (LPS) synergistically induced monocyte-mediated cytotoxicity.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016215 Macrophage-Activating Factors Factors secreted by stimulated lymphocytes that prime macrophages to become nonspecifically cytotoxic to tumors. They also modulate the expression of macrophage cell surface Ia antigens. One MAF is INTERFERON-GAMMA. Other factors antigenically distinct from IFN-gamma have also been identified. Factors, Macrophage-Activating,Macrophage Activating Factors

Related Publications

N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Macrophage-activating factor for cytotoxicity produced by a human T-cell hybridoma.
September 1984, Cellular immunology,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Identification of a T cell hybridoma which produces extraordinary quantities of macrophage activating factor.
January 1982, Advances in experimental medicine and biology,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Identification of a T cell hybridoma that produces large quantities of macrophage-activating factor.
September 1982, The Journal of experimental medicine,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6).
November 1987, European journal of biochemistry,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
A human T-T-cell hybridoma-derived lymphocyte chemoattractant factor.
April 1986, Cellular immunology,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Dendritic cell activating factor produced by mouse macrophage hybridoma.
January 1988, Microbiology and immunology,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Inhibition of interleukin 2 production and alteration of interleukin 2 mRNA processing by human T-T cell hybridoma-derived suppressor factors.
October 1994, Hybridoma,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Human macrophage-activating factors for cytotoxicity. I. Establishment of a human T-cell hybridoma that produces macrophage-activating factors for cytotoxicity.
January 1987, Microbiology and immunology,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Natural killer (NK) cell activating factor produced by a human T-cell hybridoma.
January 1991, Microbiology and immunology,
N Higashi, and M Higuchi, and N Hanada, and J Oeda, and Y Kobayashi, and T Osawa
Identification of a T cell-derived b cell growth factor distinct from interleukin 2.
March 1982, The Journal of experimental medicine,
Copied contents to your clipboard!